Table 1.
Characteristics of included studies.
| Author | Sample (T/C) | Age (T/C, year) | Male (T/C, %) | Course of disease (year) | Cardiac function grade (T/C) | Dose of shengmai injection | Basic treatment∗ | Outcomes | ||
|---|---|---|---|---|---|---|---|---|---|---|
| II | III | IV | ||||||||
| Chen and Wang 2010 [29] | 50/50 | 56.5/47.8 | 62/68 | — | 8/10 | 37/34 | 5/6 | 60 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG | 1, 2, 3, 4, 5 |
| Chi 2017 [30] | 40/40 | 63.1 | 57.5/67.5 | 9.4 | 17 | 45 | 18 | 50 ml, q.d, 4 weeks | Diuretics, ARB, β-blockers, CG | 1, 2, 8 |
| Ding 2012 [23] | 40/40 | 70.7/72.6 | 45/37.5 | 8.70/8.9 | — | 30/31 | 10/9 | 40 ml, q.d, 1 week | Diuretics, ACEI, ARB, β-blockers, CG, nitroglycerin | 2, 3, 4, 8 |
| Dou 2010 [31] | 30/23 | 66.5/67.1 | 60/61 | 8.5/7.4 | 10/7 | 16/10 | 4/6 | 100 ml, q.d, 4 weeks | ACEI, β-blockers, CG | 2, 7 |
| Kong and Zhu 2004 [32] | 30/20 | 59/58 | 60/55 | 17/16 | 9/7 | 15/10 | 6/3 | 30 ml, q.d, 2 weeks | Diuretics, ACEI, CG, | 1, 2, 4, 5 |
| Lai 2018 [22] | 65/65 | 61.6/65.1 | 65/68 | 11.3/12 | 24/21 | 25/25 | 16/15 | 100 ml, q.d, 1 week | ACEI, β-blockers, CG | 2, 3, 4, 5, 6, 7, 8 |
| Ni 2012 [33] | 43/41 | <80 | — | 2 | — | — | — | 50 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG, nitroglycerin | 1, 2, 6, 8 |
| Pan 2013 [34] | 34/34 | 63.5 | 82/88 | 2 | 32 | 36 | — | 60 ml, q.d,2 weeks | β-Blockers, CG, phentolamine | 1, 2, 3, 4, 5 |
| Pan 2014 [35] | 21/21 | 59.3/56.9 | 90/61 | 2 | — | — | — | 50 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, nitroglycerin, CG | 1 |
| Shi 2001, et al. [36] | 82/41 | 65.6/64.5 | 57/56 | 10.2/9.7 | 19/9 | 41/20 | 22/12 | 100 ml, q.d, 2 weeks | Diuretics, CG, nitroglycerin, antiarrhythmic medicines | 1, 3, 4, 5, 8 |
| Sun 2013 [37] | 30/30 | 61.4/60.5 | 63/60 | 5.92/5.5 | — | — | — | 60 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG, isosorbide dinitrate | 1, 2, 3, 4, 5 |
| Wang 2010 [38] | 41/41 | 63.6/64.3 | 63/39 | 5.8/6.2 | 14/15 | 21/20 | 6/5 | 40 ml, q.d, 2 weeks | Diuretics, β-blockers, CG | 1, 2 |
| Wen 2013 [39] | 32/32 | 61/64 | 56/53 | 8.5/9 | — | 18/14 | 14/15 | 50 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG, nitroglycerin | 1, 2, 3, 4, 5, 8 |
| Wu 2013 [40] | 30/22 | 62/61.5 | 60/68 | 10.5/8 | 10/7 | 17/13 | 3/2 | 60 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG | 1, 2 |
| Wu 2014 [41] | 30/30 | 61.8/61.3 | 43/47 | 2.75 | 7/7 | 19/20 | 4/3 | 40 ml, q.d, 2 weeks | Diuretics, ACEI, ARB, β-blockers, CG, nitroglycerin | 2, 7 |
| Xu 2004 [42] | 50/26 | 62/62.5 | 56/73 | 5.6/5.8 | — | 32/17 | 18/9 | 100 ml, q.d, 4 weeks | ACEI, CG, β-blockers | 1, 2, 3, 4, 5, 8 |
| Ye 2011 [43] | 30/30 | 62/64 | 60/53 | 10/10 | — | 19/18 | 11/12 | 40 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG, nitroglycerin | 2, 3, 4, 5, 8 |
| Yuan 2011 [44] | 89/89 | 45–74 | 72/83 | 8 | 74 | 66 | 49 | 50 ml, q.d, 3 weeks | Diuretics, ACEI, β-blockers, | 1, 2 |
| Zhai 2009 [45] | 30/30 | 62/63 | 60/53 | 10/10 | —-- | 17/18 | 13/12 | 40 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, nitroglycerin, CG | 1, 2, 3, 4, 5, 8 |
| Zou 2011 [46] | 30/30 | 67.4/64.3 | 63/70 | 4.5/4.8 | 7/8 | 14/12 | 9/10 | 40 ml, q.d, 2 weeks | Diuretics, ACEI, β-blockers, CG | 1, 2, 3, 4, 5 |
∗Both patients in the shengmai injection and control group received the same basic treatment in all individual randomized controlled trials. T = treatment; C = control; ACEI = angiotensin-converting enzyme inhibitors; ARB = angiotensin receptor blockers; CG = cardiac glycosides. 1: clinical efficacy; 2: left ventricular ejection fractions; 3: stroke volume; 4: cardiac output; 5: cardiac index; 6: brain natriuretic peptide; 7 : six min walk test; 8: adverse events.